Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
01/10/2020
Vaccibody announces Update on Expanded R&D Focus and Strategy
01/10/2020
Vaccibody enters into worldwide license and collaboration agreement with Genentech, a member of the Roche Group, to develop individualized neoantigen cancer vaccines
21/08/2020
VACCIBODY FINALIZES PATIENT ENROLMENT IN VB N-01 PHASE I/IIa TRIAL WITH ITS NOVEL VB10.NEO NEOANTIGEN CANCER VACCINE
12/08/2020
VACCIBODY AND NEKTAR THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1/2A STUDY ARM EVALUATING VB10.NEO IN COMBINATION WITH BEMPEGALDESLEUKIN
07/07/2020
Minutes from Extraordinary General Meeting in Vaccibody AS
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer